Annual Cash & Cash Equivalents
$9.77 M
-$21.47 M-68.72%
01 June 2022
Summary:
Pluristem Therapeutics annual cash & cash equivalents is currently $9.77 million, with the most recent change of -$21.47 million (-68.72%) on 01 June 2022. During the last 3 years, it has fallen by -$21.47 million (-68.72%).PSTI Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$8.74 M
-$1.03 M-10.52%
01 September 2022
Summary:
Pluristem Therapeutics quarterly cash and cash equivalents is currently $8.74 million, with the most recent change of -$1.03 million (-10.52%) on 01 September 2022.PSTI Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTI Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | -68.7% | -40.1% |
| 5 y5 years | +138.0% | +135.4% |
PSTI Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -77.2% | -85.5% |
Pluristem Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $8.74 M(-10.5%) |
| June 2022 | $9.77 M(-68.7%) | $9.77 M(-58.9%) |
| Mar 2022 | - | $23.79 M(+27.1%) |
| Dec 2021 | - | $18.71 M(+28.1%) |
| Sept 2021 | - | $14.61 M(-53.2%) |
| June 2021 | $31.24 M(+277.8%) | $31.24 M(+154.7%) |
| Mar 2021 | - | $12.27 M(+56.8%) |
| Dec 2020 | - | $7.82 M(+18.1%) |
| Sept 2020 | - | $6.63 M(-19.9%) |
| June 2020 | $8.27 M(+101.4%) | $8.27 M(+22.3%) |
| Mar 2020 | - | $6.76 M(-7.4%) |
| Dec 2019 | - | $7.30 M(+96.5%) |
| Sept 2019 | - | $3.71 M(-9.5%) |
| June 2019 | $4.11 M(-53.5%) | $4.11 M(-56.9%) |
| Mar 2019 | - | $9.54 M(+40.3%) |
| Dec 2018 | - | $6.80 M(-19.4%) |
| Sept 2018 | - | $8.43 M(-4.4%) |
| June 2018 | $8.82 M(+87.4%) | $8.82 M(+48.5%) |
| Mar 2018 | - | $5.94 M(-30.8%) |
| Dec 2017 | - | $8.58 M(-30.2%) |
| Sept 2017 | - | $12.29 M(+161.2%) |
| June 2017 | $4.71 M(-24.4%) | $4.71 M(-11.5%) |
| Mar 2017 | - | $5.32 M(-27.5%) |
| Dec 2016 | - | $7.33 M(+20.3%) |
| Sept 2016 | - | $6.10 M(-2.0%) |
| June 2016 | $6.22 M(-72.5%) | $6.22 M(+15.2%) |
| Mar 2016 | - | $5.40 M(+9.2%) |
| Dec 2015 | - | $4.95 M(-54.2%) |
| Sept 2015 | - | $10.80 M(-52.2%) |
| June 2015 | $22.63 M(+403.6%) | $22.63 M(+153.0%) |
| Mar 2015 | - | $8.94 M(+28.5%) |
| Dec 2014 | - | $6.96 M(+22.9%) |
| Sept 2014 | - | $5.66 M(+26.0%) |
| June 2014 | $4.49 M(-50.1%) | $4.49 M(+23.5%) |
| Mar 2014 | - | $3.64 M(-21.4%) |
| Dec 2013 | - | $4.63 M(-46.2%) |
| Sept 2013 | - | $8.60 M(-4.5%) |
| June 2013 | $9.01 M(-4.1%) | $9.01 M(-67.6%) |
| Mar 2013 | - | $27.82 M(+18.1%) |
| Dec 2012 | - | $23.55 M(-60.9%) |
| Sept 2012 | - | $60.19 M(+541.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2012 | $9.39 M(-78.1%) | $9.39 M(-72.0%) |
| Mar 2012 | - | $33.50 M(-9.9%) |
| Dec 2011 | - | $37.16 M(+172.6%) |
| Sept 2011 | - | $13.63 M(-68.2%) |
| June 2011 | $42.83 M(+2605.6%) | $42.83 M(-4.5%) |
| Mar 2011 | - | $44.87 M(+846.7%) |
| Dec 2010 | - | $4.74 M(+320.5%) |
| Sept 2010 | - | $1.13 M(-28.8%) |
| June 2010 | $1.58 M(-32.3%) | $1.58 M(+41.5%) |
| Mar 2010 | - | $1.12 M(-19.1%) |
| Dec 2009 | - | $1.38 M(-35.4%) |
| Sept 2009 | - | $2.14 M(-8.5%) |
| June 2009 | $2.34 M(+624.1%) | $2.34 M(+35.7%) |
| Mar 2009 | - | $1.72 M(-21.4%) |
| Dec 2008 | - | $2.19 M(+10.9%) |
| Sept 2008 | - | $1.98 M(+512.4%) |
| June 2008 | $323.00 K(-80.5%) | $323.00 K(-81.7%) |
| Mar 2008 | - | $1.76 M(+281.8%) |
| Dec 2007 | - | $462.00 K(-17.8%) |
| Sept 2007 | - | $562.00 K(-66.0%) |
| June 2007 | $1.65 M(-30.4%) | $1.65 M(-63.8%) |
| Mar 2007 | - | $4.56 M(+441.2%) |
| Dec 2006 | - | $842.90 K(-50.5%) |
| Sept 2006 | - | $1.70 M(-28.3%) |
| June 2006 | $2.37 M(+25.7%) | $2.37 M(+485.1%) |
| Mar 2006 | - | $405.80 K(-60.2%) |
| Dec 2005 | - | $1.02 M(-29.5%) |
| Sept 2005 | - | $1.45 M(-23.5%) |
| June 2005 | $1.89 M(+182.5%) | $1.89 M(-19.7%) |
| Mar 2005 | - | $2.35 M(+787.1%) |
| Dec 2004 | - | $265.40 K(+20.2%) |
| Sept 2004 | - | $220.80 K(-67.0%) |
| June 2004 | $668.90 K(+31.9%) | $668.90 K(-23.9%) |
| Mar 2004 | - | $879.10 K(+715.5%) |
| Dec 2003 | - | $107.80 K(-78.3%) |
| Sept 2003 | - | $495.70 K(-2.3%) |
| June 2003 | $507.30 K(>+9900.0%) | $507.30 K(>+9900.0%) |
| Mar 2003 | - | $200.00(0.0%) |
| Dec 2002 | - | $200.00(-99.7%) |
| Sept 2002 | - | $71.00 K(+7000.0%) |
| June 2002 | $1000.00 | $1000.00 |
FAQ
- What is Pluristem Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pluristem Therapeutics?
- What is Pluristem Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Pluristem Therapeutics?
What is Pluristem Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of PSTI is $9.77 M
What is the all time high annual cash & cash equivalents for Pluristem Therapeutics?
Pluristem Therapeutics all-time high annual cash & cash equivalents is $42.83 M
What is Pluristem Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PSTI is $8.74 M
What is the all time high quarterly cash and cash equivalents for Pluristem Therapeutics?
Pluristem Therapeutics all-time high quarterly cash and cash equivalents is $60.19 M